TIMI 64A was a phase 2a randomized, double-blind, placebo-controlled parallel-designed study to evaluate the safety, pharmacokinetics, and pharmacodynamic effects of MEDI5884 in subjects with stable coronary heart disease.
MAIN RESULTS:
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease
Arterioscler Thromb Vasc Biol. 2021 Dec;41(12):3005-3014.